by telrheum | May 27, 2024 | Sjögren’s Syndrome, Systemic Sclerosis
Study Background: This research focuses on finding reliable blood biomarkers to diagnose Interstitial Lung Disease (ILD) in patients with autoimmune diseases, specifically rheumatoid arthritis (RA) and systemic sclerosis (SSc). ILD is a serious complication in these...
by telrheum | May 26, 2024 | Osteoarthritis, Antibody Therapy, Degenerative Arthritis
The study titled “Efficacy, Safety, Pharmacokinetics and Immunogenicity of Repeated Dosing of GSK3858279 in Patients with Knee Osteoarthritis” aimed to evaluate a new treatment for knee osteoarthritis (OA) pain. This treatment, GSK3858279, is a human monoclonal...
by telrheum | May 25, 2024 | Biologic Therapy, Colitis, IL-23 Inhibitors, Interleukin Inhibitors, tumour necrosis factor inhibitors (TNFis)
Background Ulcerative colitis is a chronic inflammatory condition affecting the colon. A recent study investigated the effectiveness of combining two drugs, Simponi, which blocks tumor necrosis factor-alpha, and Tremfya, which inhibits interleukin-23. This combination...
by telrheum | May 25, 2024 | Spondyloarthritis, Biologic Therapy
Anti-IL-17 Drugs: A Guide Interleukin-17 (IL-17) is a protein that plays a crucial role in the body’s immune response. While it’s important for fighting infections, too much IL-17 can lead to inflammation and various autoimmune diseases, such as psoriasis, psoriatic...
by telrheum | May 25, 2024 | Interstitial Lung Disease, JAK Inhibitor, Systemic Sclerosis
This study explored the effectiveness and safety of nintedanib (NTB), a drug approved for progressive fibrosing interstitial lung disease (PF-ILD), in combination with immunosuppressive agents (IS) for treating connective tissue disease-associated PF-ILD (CTD-PF-ILD)....